What are mast cell disorders, their types, diagnostic criteria, and treatment options?

Mast Cell Disorders: Overview and Clinical Management

Mast cell disorders are a heterogeneous group of conditions characterized by pathologic accumulation and/or inappropriate activation of mast cells in tissues, resulting in symptoms from mediator release and tissue infiltration 1, 2.

Classification

Mast cell disorders are divided into three major categories:

1. Cutaneous Mastocytosis

• Urticaria Pigmentosa (UP): Most common form in children (70-90% of cases), presenting as red-brown-yellow lesions 1
• Mastocytomas: Solitary lesions, often present at birth
• Diffuse Cutaneous Mastocytosis (DCM): Rare (1-3% of cases) but severe, can present with extensive bullae, hemorrhagic blisters, and life-threatening complications including hypotension, anemia, and hypovolemic shock 1
• Telangiectasia Macularis Eruptiva Persistans (TMEP): Least common, rarely in children 1

2. Systemic Mastocytosis (SM)

The 2022 International Consensus Classification requires 1 major criterion plus 1 minor criterion, OR 3 minor criteria 2:

Major criterion:

• Multifocal dense infiltrates of ≥15 tryptase/CD117-positive mast cells in bone marrow or extracutaneous organs

Minor criteria:

• 25% atypical mast cell morphology

• KIT D816V or other activating KIT mutation
• Aberrant CD2/CD25/CD30 expression on mast cells
• Serum tryptase >20 ng/mL (unless associated with another myeloid neoplasm)

SM subtypes include:

• Indolent SM (ISM)/Smoldering SM (SSM)
• Aggressive SM (ASM)
• SM with associated myeloid neoplasm (SM-AMN)
• Mast cell leukemia 3

3. Mast Cell Activation Syndrome (MCAS)

Diagnosis requires ALL three criteria 4:

• Episodic systemic symptoms affecting ≥2 organ systems
• Objective biochemical evidence of mast cell mediator release (elevated tryptase, histamine, PGD2, or LTC4 metabolites during symptomatic episodes)
• Response to medications blocking mediator production or receptor binding

Diagnostic Approach

For Suspected Cutaneous Mastocytosis:

Initial evaluation 1:

• Physical examination for Darier's sign (urtication/flare upon rubbing lesions)
• 3mm punch skin biopsy with H&E, Giemsa, tryptase, and KIT immunostaining
• c-kit mutational analysis
• Baseline serum tryptase
• Complete blood count with differential

Proceed to bone marrow biopsy if 1:

• Tryptase >20 μg/L
• Severe recurrent systemic symptoms (GI, flushing, syncope, cyanotic spells)
• Organomegaly or significant lymphadenopathy
• Skin lesions persist after puberty
• No response to initial symptomatic therapy

Risk Stratification in SM:

Identify poor-risk mutations (ASXL1, RUNX1, SRSF2, NRAS) which refine prognosis 3. Tryptase levels >20 μg/L indicate increased mast cell burden and warrant close observation; progressively higher values are increasingly concerning 1.

Treatment Strategy

Pediatric Cutaneous Mastocytosis:

The primary objective is stabilizing mediator release, NOT cytoreduction 1. Cytoreductive therapy is strongly discouraged except in life-threatening aggressive variants 1.

Stepwise approach:

1. Trigger avoidance 1:

   • Temperature extremes (hot/cold)
   • Anxiety and stress
   • Specific triggers identified per patient

2. First-line therapy - H1 antihistamines 1:

   • Diphenhydramine, hydroxyzine, or cetirizine
   • Both sedating and non-sedating options effective
   • Monitor for cardiotoxicity with high doses

3. Add H2 antihistamines for severe symptoms 1:

   • Ranitidine or famotidine (age-appropriate)
   • Particularly for GI symptoms, gastric hypersecretion
   • If inadequate, escalate to proton pump inhibitors

4. Oral cromolyn sodium for GI symptoms 1:

   • Effective for diarrhea, abdominal pain, nausea, vomiting
   • May help with pruritus and cognitive symptoms

5. Emergency management 1:

   • Epinephrine IM in recumbent position for acute mast cell activation with hypotension, wheezing, or laryngeal edema
   • All patients should have epinephrine auto-injectors available

Adult Systemic Mastocytosis:

For ISM/SSM 3:

• Focus on anaphylaxis prevention
• Symptom control with antihistamines
• Osteoporosis treatment when indicated
• Epinephrine auto-injectors mandatory

For Advanced SM (ASM, SM-AMN, mast cell leukemia) 3:

• Avapritinib: First-line tyrosine kinase inhibitor (TKI) producing deep biochemical, histological, and molecular responses
• Midostaurin: Alternative TKI option
• Cladribine: Role for mast cell debulking
• Interferon-α: Diminishing role in TKI era
• Imatinib: Only for rare imatinib-sensitive KIT mutations (NOT D816V)
• Allogeneic stem cell transplant: Consider for SM-AMN with aggressive disease like acute leukemia

Critical Management Points

Education is essential 1: Inform parents, caregivers, teachers, and healthcare providers that cutaneous mastocytosis is NOT contagious. Provide written protocols for fever, vaccinations, dental work, imaging with contrast, and surgery.

Prognosis in children: 75% of mastocytomas and 56% of UP cases show complete resolution 1. Symptoms typically most severe in first 6-18 months after onset 1.

Anesthesia considerations 1: Obtain baseline PT/PTT before invasive procedures. Measure tryptase before and after surgery to document mast cell activation if adverse events occur.

Multidisciplinary referral to specialized centers is strongly recommended 2, particularly for collaboration with allergists (anaphylaxis management), anesthesiologists (procedures), and high-risk obstetricians (pregnancy).